The discovery of mutations and the subsequent development of the first KIT tyrosine kinase inhibitor (TKI), imatinib (IM), in 2001, revolutionized the treatment of newly diagnosed locally advanced and metastatic GIST patients, who are commonly resistant to conventional chemotherapy [5]. Here, KIT is linked to gastrointestinal stromal tumor.